This Bavarian Biotech Offers Better Drug Delivery to Boost Efficacy and Tolerability

This week, we’re in the Bavarian region of Germany to check out XL-Protein, a biotech that improves drug delivery by modifying the drugs we use to help them stay in the body for longer.

Mission: XL-Protein has found a way to slow down the speed at which a drug is removed from the body. PASylation attaches a polypeptide containing proline, alanine, and serine to the therapeutic compound, which produces a larger, bulkier fusion peptide. This modification is enough to significantly slow down the clearance of the drug.

This has many benefits for the drug, including an increased half-life and enhanced therapeutic action, which means less frequent, lower doses are sufficient to treat the patient. So far, the technology has been combined with drugs for a wide range of diseases, including HIV, multiple sclerosis, and cancer.

Comment: With drug development being such a long process, it is important to get the absolute best out of those that reach the market. By combining XL-Protein’s technique with drugs that are being brought to the market, patients may be able to enjoy an even better quality of treatment.

XL-Protein is one of many biotechs that are active in this field. One of the most exciting technologies that I have come across in this area is a caterpillar-like robot, which can be navigated through the body by applying different magnetic fields.

Images – Jazzmany /

Support good journalism, subscribe to Labiotech Insider

Labiotech Insider

If you liked this post and want to read more good journalism, support us by joining Labiotech Insider. Our Insider membership gives you access to exclusive content and other advantages.